Literature DB >> 18689701

Detection of Chlamydia trachomatis ocular infection in trachoma-endemic communities by rRNA amplification.

Jon L Yang1, Kevin C Hong, Julius Schachter, Jeanne Moncada, Takele Lekew, Jenafir I House, Zhaoxia Zhou, Melissa D Neuwelt, Tina Rutar, Colleen Halfpenny, Neelima Shah, John P Whitcher, Thomas M Lietman.   

Abstract

PURPOSE: Trachoma remains the leading infectious cause of blindness worldwide. The World Health Organization (WHO) recommends mass antibiotic distributions in its strategy to eliminate blinding trachoma. To determine the most effective antibiotic treatment strategy, it is essential to have a diagnostic test that can correctly measure the true status of ocular Chlamydia trachomatis infection in individuals, particularly after treatment. A newer ribosomal ribonucleic acid (rRNA)-based amplification test was compared with the current DNA-based polymerase chain reaction (PCR) for the detection of C. trachomatis.
METHODS: An rRNA-based assay and PCR were performed on swab specimens taken from the right upper tarsal conjunctiva of 240 children aged 1 to 5 years living among 16 endemic villages in the Gurage Zone, Ethiopia.
RESULTS: The rRNA-based test detected ocular C. trachomatis infection in 142 (59%) subjects compared with 67 (28%) detected by PCR (McNemar's test, P < 0.0001). The rRNA-based test gave positive results for all subjects who were positive by PCR and detected infection in 75 (31%) additional subjects.
CONCLUSIONS: The rRNA-based test appears to have significantly greater sensitivity than PCR for the detection of ocular C. trachomatis infection in children in trachoma-endemic villages. The increased sensitivity of the rRNA-based test may be due to its ability to detect low levels of C. trachomatis infection in individuals, which can occur especially after antibiotic treatment. Data from past studies in which PCR was used to assess the prevalence of infectious trachoma after community-wide antibiotic treatments could have underestimated the true prevalence of infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18689701     DOI: 10.1167/iovs.08-2247

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  Comparison of the Abbott m2000 RealTime CT assay and the Cepheid GeneXpert CT/NG assay to the Roche Amplicor CT assay for detection of Chlamydia trachomatis in ocular samples from Tanzania.

Authors:  Laura Dize; Sheila West; James A Williams; Barbara Van Der Pol; Thomas C Quinn; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

Review 2.  Chlamydial infection during trachoma monitoring: are the most difficult-to-reach children more likely to be infected?

Authors:  Jeremy D Keenan; J Moncada; T Gebre; B Ayele; M C Chen; S N Yu; P M Emerson; N E Stoller; C E McCulloch; B D Gaynor; J Schachter
Journal:  Trop Med Int Health       Date:  2011-11-28       Impact factor: 2.622

3.  How reliable are tests for trachoma?--a latent class approach.

Authors:  Craig W See; Wondu Alemayehu; Muluken Melese; Zhaoxia Zhou; Travis C Porco; Stephen Shiboski; Bruce D Gaynor; John Eng; Jeremy D Keenan; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-03       Impact factor: 4.799

4.  Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.

Authors:  Jeremy D Keenan; Craig W See; Jeanne Moncada; Berhan Ayele; Teshome Gebre; Nicole E Stoller; Charles E McCulloch; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

5.  Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.

Authors:  Jeremy D Keenan; Berhan Ayele; Teshome Gebre; Jeanne Moncada; Nicole E Stoller; Zhaoxia Zhou; Travis C Porco; Charles E McCulloch; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2011-11-17       Impact factor: 9.079

6.  Chlamydia trachomatis growth inhibition and restoration of LDL-receptor level in HepG2 cells treated with mevastatin.

Authors:  Yuriy K Bashmakov; Nailya A Zigangirova; Yulia P Pashko; Lidia N Kapotina; Ivan M Petyaev
Journal:  Comp Hepatol       Date:  2010-01-28

7.  Trachoma rapid assessments in Unity and Northern Bahr-el-Ghazal States, Southern Sudan.

Authors:  Emily Robinson; Lucia W Kur; Aggrey Ndyaba; Mounir Lado; Juma Shafi; Emmanuel Kabare; R Scott McClelland; Jan H Kolaczinski
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

8.  Molecular Diagnosis of Sexually Transmitted Chlamydia trachomatis in the United States.

Authors:  April L Harkins; Erik Munson
Journal:  ISRN Obstet Gynecol       Date:  2011-06-12

Review 9.  Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.

Authors:  Diane K Lavett; Van C Lansingh; Marissa J Carter; Kristen A Eckert; Juan C Silva
Journal:  ScientificWorldJournal       Date:  2013-05-19

10.  Field evaluation of the Cepheid GeneXpert Chlamydia trachomatis assay for detection of infection in a trachoma endemic community in Tanzania.

Authors:  Alexander Jenson; Laura Dize; Harran Mkocha; Beatriz Munoz; Jennifer Lee; Charlotte Gaydos; Thomas Quinn; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2013-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.